CAPR · As filed with the SEC
Capricor Therapeutics balance sheet, by fiscal year
The statement as Capricor Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED BALANCE SHEETS · USD
| USD | FY2025 Dec 31, 2025 | FY2024 Dec 31, 2024 | FY2023 Dec 31, 2023 | FY2022 Dec 31, 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| CURRENT ASSETS | ||||
| Cash and cash equivalents | 287,847,312 | 11,286,996 | 14,694,857 | 9,603,242 |
| Marketable securities | — | 140,228,881 | 24,792,846 | 31,818,020 |
| Marketable securities | 30,281,603 | — | — | — |
| Receivables | 59,167 | 10,368,489 | 10,371,993 | 547,580 |
| Prepaid expenses and other current assets | 4,751,674 | 1,500,901 | 995,776 | 919,892 |
| TOTAL CURRENT ASSETS | 322,939,756 | 163,385,267 | 50,855,472 | 42,888,734 |
| PROPERTY AND EQUIPMENT, net | 18,312,238 | 5,561,597 | 5,560,641 | 4,588,030 |
| OTHER ASSETS | ||||
| Lease right-of-use assets, net | 13,537,820 | 1,312,522 | 2,050,042 | 2,349,974 |
| Other assets | 1,159,480 | 221,700 | 268,172 | 268,172 |
| TOTAL ASSETS | 355,949,294 | 170,481,086 | 58,734,327 | 50,094,910 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||
| CURRENT LIABILITIES | ||||
| Accounts payable and accrued expenses | — | 8,191,377 | 6,222,762 | 4,834,683 |
| Accounts payable and accrued expenses, related party | — | — | — | 89,234 |
| Accounts payable and accrued expenses, related party | — | — | 27,479 | — |
| Accounts payable | 1,654,754 | — | — | — |
| Accrued expenses | 15,557,646 | — | — | — |
| Lease liabilities, current | 202,376 | 834,799 | 749,112 | 682,039 |
| CIRM liability, current | 6,421,984 | — | — | — |
| Deferred revenue, current | 12,000,000 | 12,000,000 | 24,270,465 | 17,980,599 |
| TOTAL CURRENT LIABILITIES | 35,836,760 | 21,026,176 | 31,269,818 | 23,586,555 |
| LONG-TERM LIABILITIES | ||||
| CIRM liability | — | — | 3,376,259 | 3,376,259 |
| CIRM liability, net of current | 0 | 3,376,259 | — | — |
| Lease liabilities, net of current | 14,320,389 | 616,315 | 1,486,783 | 1,878,070 |
| Deferred revenue, net of current | — | — | 0 | 9,467,932 |
| TOTAL LONG-TERM LIABILITIES | 14,320,389 | 3,992,574 | 4,863,042 | 14,722,261 |
| TOTAL LIABILITIES | 50,157,149 | 25,018,750 | 36,132,860 | 38,308,816 |
| STOCKHOLDERS' EQUITY | ||||
| Common stock, $0.001 par value, 100,000,000 shares authorized, 57,370,909 and 45,582,288 shares issued and outstanding, respectively | 57,371 | 45,582 | 31,148 | 25,241 |
| Additional paid-in capital | 610,330,105 | 344,224,338 | 181,701,859 | 148,735,420 |
| Accumulated other comprehensive income | 283,154 | 1,026,955 | 235,813 | 105,244 |
| Accumulated deficit | (304,878,485) | (199,834,539) | (159,367,353) | (137,079,811) |
| TOTAL STOCKHOLDERS' EQUITY | 305,792,145 | 145,462,336 | 22,601,467 | 11,786,094 |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | 355,949,294 | 170,481,086 | 58,734,327 | 50,094,910 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.
Data on this page was fetched . The filing on SEC.gov is the record.